- Home
- MLCO vs CGON Comparison
MLCO vs CGON Comparison
Compare MLCO & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLCO
- CGON
- Stock Information
- Founded
- MLCO 2004
- CGON 2010
- Country
- MLCO Hong Kong
- CGON United States
- Employees
- MLCO N/A
- CGON 61
- Industry
- MLCO Hotels/Resorts
- CGON
- Sector
- MLCO Consumer Discretionary
- CGON
- Exchange
- MLCO Nasdaq
- CGON NYSE
- Market Cap
- MLCO 2.9B
- CGON 2.2B
- IPO Year
- MLCO 2006
- CGON 2024
- Fundamental
- Price
- MLCO $6.12
- CGON $32.84
- Analyst Decision
- MLCO Strong Buy
- CGON Strong Buy
- Analyst Count
- MLCO 6
- CGON 8
- Target Price
- MLCO $9.85
- CGON $63.88
- AVG Volume (30 Days)
- MLCO 2.9M
- CGON 396.6K
- Earning Date
- MLCO 11-05-2024
- CGON 11-12-2024
- Dividend Yield
- MLCO N/A
- CGON N/A
- EPS Growth
- MLCO N/A
- CGON N/A
- EPS
- MLCO N/A
- CGON N/A
- Revenue
- MLCO $4,540,808,000.00
- CGON $684,000.00
- Revenue This Year
- MLCO $24.63
- CGON $411.76
- Revenue Next Year
- MLCO $5.76
- CGON $405.27
- P/E Ratio
- MLCO N/A
- CGON N/A
- Revenue Growth
- MLCO 50.42
- CGON 258.12
- 52 Week Low
- MLCO $4.78
- CGON $25.77
- 52 Week High
- MLCO $9.56
- CGON $50.23
- Technical
- Relative Strength Index (RSI)
- MLCO 35.46
- CGON 41.08
- Support Level
- MLCO $6.13
- CGON $35.12
- Resistance Level
- MLCO $6.33
- CGON $40.47
- Average True Range (ATR)
- MLCO 0.27
- CGON 1.69
- MACD
- MLCO -0.09
- CGON -0.28
- Stochastic Oscillator
- MLCO 6.40
- CGON 4.57
About MLCO Melco Resorts & Entertainment Limited
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao with the rest largely from the Philippines as of 2019.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.